newsfilter
← Latest News
Business Wire·

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary